Condition

Chronic myeloid leukemia

Clinical trials and treatment information for Chronic myeloid leukemia

64K
People Affected
30
Active Trials
13K
New Cases/Year
23K
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Ponatinib
93% Effectiveness• 88% Confidence• 45% Safety• 43 trials• 3K participants
HIGH EvidenceGood ValueDose: 45 mg daily, often reduced to 15-30 mg daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe

Time to Effect

3-6 months for major response

Duration

Lifetime

Response Rate

55%

Remission Rate

35%

Common Side Effects:

Arterial occlusive events (AOEs): 25%
Hypertension: 65%
Rash: 45%
Abdominal pain: 35%
Fatigue: 35%
Pancreatitis: 15%
Myelosuppression: 35%

Annual Cost of Care

Drug Cost

$180,000

Monitoring

$3,500

Side Effects

$5,000

Total Annual

$188,500

Cost-Effectiveness

GOOD

QALYs Gained

7

Cost per Remission

$538,571

Cost per Responder

$342,727

Treatment Outcomes
Primary Outcomes
BCR-ABL1/ABL ratio (Major Molecular Response - MMR)BCR-ABL1/ABL ratio (IS): 10%
-99% (-9.9% IS (to <= 0.1% IS))
Philadelphia Chromosome (Ph+) Metaphases (Complete Cytogenetic Response - CCyR)Ph+ metaphases: 80%
-100% (-80% (to 0% Ph+ metaphases))
White Blood Cell (WBC) CountWBC count: 35 x 10^9/L
-80% (-28 x 10^9/L)
Platelet CountPlatelet count: 600 x 10^9/L
-58.33% (-350 x 10^9/L)
Secondary Benefits
Spleen Palpable Distance below Costal MarginSpleen palpable: 6 cm below costal margin
-83.33% (-5 cm (to 1 cm below costal margin))
ECOG Performance StatusECOG Performance Status: 2/5
-100% (-2 points (to 0/5))
Hemoglobin LevelHemoglobin: 10 g/dL
+30% (+3 g/dL)
Common Side Effects
Arterial occlusive events (AOEs)
+25%
Hypertension
+65%
Rash
+45%

Clinical Trial Phases:

Phase 2Phase 3Phase 4
2
Dasatinib
92% Effectiveness• 92% Confidence• 60% Safety• 142 trials• 15K participants
HIGH EvidenceModerate ValueDose: 100 mg daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe

Time to Effect

1-3 months for initial molecular response

Duration

Lifetime (or 5+ years for TFR attempts)

Response Rate

80%

Remission Rate

50%

Common Side Effects:

Fluid retention (pleural effusion, peripheral edema): 45%
Myelosuppression: 35%
Diarrhea: 35%
Headache: 25%
Nausea: 25%
Fatigue: 25%

Annual Cost of Care

Drug Cost

$120,000

Monitoring

$2,000

Side Effects

$1,500

Total Annual

$123,500

Cost-Effectiveness

MODERATE

QALYs Gained

11

Cost per Remission

$247,000

Cost per Responder

$154,375

Treatment Outcomes
Primary Outcomes
BCR-ABL1 Transcript Level (International Scale)10% IS
-99% (-9.9% IS)
Philadelphia Chromosome Positive Metaphases (Bone Marrow)100% Ph+ metaphases
-100% (-100% Ph+ metaphases)
White Blood Cell Count50 x 10^9/L
-84% (-42 x 10^9/L)
Platelet Count600 x 10^9/L
-50% (-300 x 10^9/L)
Secondary Benefits
Spleen Size (Palpable below costal margin)7 cm below costal margin
-100% (-7 cm)
FACIT-Fatigue Scale Score20/52 (higher is less fatigue)
+75% (+15 points)
Peripheral Blood Blast Cells5%
-90% (-4.5%)
Common Side Effects
Fluid retention (pleural effusion, peripheral edema)
+45%
Myelosuppression
+35%
Diarrhea
+35%

Clinical Trial Phases:

Phase 3Phase 4
3
Nilotinib
91% Effectiveness• 92% Confidence• 58% Safety• 141 trials• 12K participants
HIGH EvidenceModerate ValueDose: 300 mg twice daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe

Time to Effect

1-3 months for initial molecular response

Duration

Lifetime (or 5+ years for TFR attempts)

Response Rate

78%

Remission Rate

48%

Common Side Effects:

Cardiovascular events (QT prolongation, atherosclerosis): 15%
Myelosuppression: 25%
Nausea/vomiting: 25%
Headache: 25%
Fatigue: 25%
Rash: 25%
Pancreatitis: 7%

Annual Cost of Care

Drug Cost

$130,000

Monitoring

$2,500

Side Effects

$1,200

Total Annual

$133,700

Cost-Effectiveness

MODERATE

QALYs Gained

10.8

Cost per Remission

$278,542

Cost per Responder

$171,410

Treatment Outcomes
Primary Outcomes
BCR-ABL1 Transcript Levels (IS)Median ~80-100% IS (pre-treatment)
-99.9% (Reduction to "99.9%)
Secondary Benefits
Quality of Life (EORTC QLQ-CML24 Global Health Status/QoL score)Median 55/100 (lower scores indicate worse QoL)
+20% (+11 points)
Fatigue Score (FACIT-Fatigue Scale)Median 30/52 (lower scores indicate more fatigue)
+15% (+4.5 points)
Hemoglobin LevelMedian 10.0 g/dL
+20% (+2.0 g/dL)
Common Side Effects
Cardiovascular events (QT prolongation, atherosclerosis)
+15%
Myelosuppression
+25%
Nausea/vomiting
+25%

Clinical Trial Phases:

Phase 3Phase 4
4
Imatinib
90% Effectiveness• 95% Confidence• 65% Safety• 306 trials• 20K participants
HIGH EvidenceExcellent ValueDose: 400 mg daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe

Time to Effect

3-6 months for major response

Duration

Lifetime (or 5+ years for TFR attempts)

Response Rate

75%

Remission Rate

45%

Common Side Effects:

Fluid retention (edema): 60%
Muscle cramps: 35%
Nausea/vomiting: 40%
Diarrhea: 35%
Fatigue: 35%
Rash: 25%
Myelosuppression: 15%

Annual Cost of Care

Drug Cost

$8,000

Monitoring

$2,000

Side Effects

$750

Total Annual

$10,750

Cost-Effectiveness

EXCELLENT

QALYs Gained

10

Cost per Remission

$23,889

Cost per Responder

$14,333

Treatment Outcomes
Primary Outcomes
White Blood Cell (WBC) Count100 x 10^9/L
-95% (-95 x 10^9/L)
Philadelphia Chromosome-positive (Ph+) Metaphases95% of metaphases
-99.5% (-94.5 percentage points)
BCR-ABL1 Transcript Levels (International Scale - IS)100% (1.0 IS)
-99.9% (-99.9 percentage points)
Spleen Size (below costal margin)10 cm below costal margin
-80% (-8 cm)
Secondary Benefits
Fatigue (FACIT-Fatigue score)FACIT-Fatigue score: 25/52
+40% (+10 points)
Quality of Life (EORTC QLQ-CML24 Global Health Status/QoL)Global Health Status/QoL score: 60/100
+15% (+9 points)
Platelet Count600 x 10^9/L
-65% (-390 x 10^9/L)
Common Side Effects
Fluid retention (edema)
+60%
Muscle cramps
+35%
Nausea/vomiting
+40%

Clinical Trial Phases:

Phase 3Phase 4
5
Bosutinib
88% Effectiveness• 90% Confidence• 60% Safety• 43 trials• 8K participants
HIGH EvidenceModerate ValueDose: 400 mg daily with food
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe

Time to Effect

3-6 months for major response

Duration

Lifetime

Response Rate

65%

Remission Rate

40%

Common Side Effects:

Diarrhea: 75%
Nausea: 45%
Vomiting: 35%
Increased transaminases (liver enzymes): 35%
Myelosuppression: 25%

Annual Cost of Care

Drug Cost

$125,000

Monitoring

$2,500

Side Effects

$1,000

Total Annual

$128,500

Cost-Effectiveness

MODERATE

QALYs Gained

10

Cost per Remission

$321,250

Cost per Responder

$197,692

Treatment Outcomes
Primary Outcomes
BCR-ABL1/ABL Ratio (IS)10% IS
-99% (-9.9% IS)
Percentage of Ph+ cells in bone marrow60% Ph+ cells
-100% (-60% Ph+ cells)
White Blood Cell (WBC) count40 x 10^9/L
-80% (-32 x 10^9/L)
Spleen Size (below costal margin)5 cm below costal margin
-60% (-3 cm below costal margin)
Secondary Benefits
Platelet Count600 x 10^9/L
-58.3% (-350 x 10^9/L)
Hemoglobin10.0 g/dL
+30% (+3.0 g/dL)
FACT-G Fatigue scoreFACT-G Fatigue score: 12/28
+25% (+3 points)
Common Side Effects
Diarrhea
+75%
Nausea
+45%
Vomiting
+35%

Clinical Trial Phases:

Phase 3Phase 4